Novavax Depreciation And Amortization vs Income Before Tax Analysis
NVAX Stock | USD 4.71 0.04 0.86% |
Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Depreciation And Amortization and its Income Before Tax accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.
Depreciation And Amortization vs Income Before Tax
Depreciation And Amortization vs Income Before Tax Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Depreciation And Amortization account and Income Before Tax. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Novavax's Depreciation And Amortization and Income Before Tax is -0.37. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Income Before Tax in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Depreciation And Amortization and Income Before Tax is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Novavax are associated (or correlated) with its Income Before Tax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Before Tax has no effect on the direction of Depreciation And Amortization i.e., Novavax's Depreciation And Amortization and Income Before Tax go up and down completely randomly.
Correlation Coefficient | -0.37 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Novavax income statement and is an important metric when analyzing Novavax profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).
Novavax fundamental ratios Correlations
Click cells to compare fundamentals
Novavax Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novavax fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Liab | 19.9M | (327.6M) | 709.8M | 1.5B | 1.2B | 1.3B | |
Total Current Liabilities | 25.8M | 322.0M | 2.4B | 2.5B | 1.6B | 1.7B | |
Total Stockholder Equity | (186.0M) | 627.2M | (351.7M) | (634.1M) | (716.9M) | (681.1M) | |
Property Plant And Equipment Net | 11.4M | 180.0M | 228.7M | 400.5M | 491.0M | 515.5M | |
Net Debt | 243.1M | (231.4M) | (1.1B) | (787.1M) | (298.3M) | (283.4M) | |
Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (4.8B) | (4.6B) | |
Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 132.6M | 139.2M | |
Cash | 78.8M | 553.4M | 1.5B | 1.3B | 578.9M | 607.9M | |
Non Current Assets Total | 75.7M | 334.3M | 421.6M | 555.3M | 711.5M | 747.0M | |
Non Currrent Assets Other | 7.5M | 13.2M | 56.7M | 28.5M | 30.3M | 31.8M | |
Cash And Short Term Investments | 78.8M | 711.0M | 1.5B | 1.3B | 578.9M | 607.9M | |
Common Stock Shares Outstanding | 24.1M | 57.6M | 74.4M | 78.2M | 100.8M | 105.8M | |
Liabilities And Stockholders Equity | 173.0M | 1.6B | 2.6B | 2.3B | 1.9B | 1.9B | |
Other Current Assets | 93.9M | 441.8M | 2.1B | 1.7B | 226.0M | 191.7M | |
Other Stockholder Equity | 1.3B | 2.5B | 3.3B | 3.6B | 4.1B | 4.3B | |
Total Liab | 359.0M | 955.3M | 2.9B | 2.9B | 2.6B | 2.7B | |
Property Plant And Equipment Gross | 11.4M | 180.0M | 258.6M | 447.8M | 566.0M | 594.3M | |
Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 1.1B | 1.2B | |
Accumulated Other Comprehensive Income | (12.5M) | 7.0M | (1.4M) | (6.4M) | 2.7M | 2.9M | |
Net Receivables | 7.5M | 262.0M | 455.0M | 82.4M | 297.2M | 312.1M | |
Non Current Liabilities Total | 333.2M | 633.2M | 538.1M | 432.8M | 937.1M | 984.0M | |
Intangible Assets | 6.5M | 5.6M | 5.7M | 4.8M | 4.3M | 4.1M | |
Short Long Term Debt Total | 321.9M | 322.0M | 454.0M | 549.8M | 280.6M | 294.7M | |
Common Stock Total Equity | 3.8M | 324K | 714K | 764K | 878.6K | 1.3M | |
Short Term Debt | 1.3M | 322.0M | 130.5M | 352.1M | 28.1M | 43.9M | |
Common Stock | 324K | 714K | 764K | 868K | 1.4M | 1.3M | |
Long Term Debt | 320.6M | 322.0M | 323.5M | 166.5M | 168.0M | 114.6M | |
Inventory | (83.0M) | (166.7M) | (2.0B) | 36.7M | 41.7M | 43.8M | |
Property Plant Equipment | 11.4M | 180.0M | 228.7M | 400.5M | 460.6M | 483.6M | |
Other Liab | 2.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
Current Deferred Revenue | 1.7M | 273.2M | 1.4B | 370.1M | 241.3M | 140.2M | |
Other Assets | 1.1M | 5.4M | 16.6M | 28.5M | 32.7M | 34.4M | |
Good Will | 51.2M | 135.4M | 131.5M | 126.3M | 127.5M | 133.8M | |
Net Tangible Assets | (242.8M) | 486.1M | (487.9M) | (760.4M) | (684.4M) | (650.1M) | |
Retained Earnings Total Equity | (1.3B) | (1.4B) | (1.9B) | (3.6B) | (3.3B) | (3.1B) | |
Long Term Debt Total | 319.2M | 320.6M | 322.0M | 323.5M | 372.0M | 234.9M | |
Capital Surpluse | 1.1B | 1.3B | 2.5B | 3.4B | 3.9B | 4.0B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.41) | Revenue Per Share 9.762 | Quarterly Revenue Growth (0.18) | Return On Assets (0.17) | Return On Equity (8.98) |
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.